17 October 2025 - Report will be subject of Midwest CEPAC meeting in May 2026; draft scoping document open to public comment until 5 November 2025.

The ICER announced today that it will assess the comparative clinical effectiveness and value of oveporexton (Takeda) for narcolepsy type 1.

Read ICER Announcement